Abstract:Chimeric fusion proteins, produced by genetic engineering, are currently made up of effector peptides, for example, a ligand-binding portion of a cytokine or growth factor, extracellular domains of lymphocyte antigens, or a toxin linked to a suitable fusion partner. This review covers eight fusion proteins that have received regulatory approval for human therapy: etanercept, belatacept, abatacept, alefacept, rilonacept, romiplostim, aflibercept, and denileukin-diftitox. Important requirements for an effective fusion protein are effective targeting and binding, cytotoxicity, and a stable molecule with an extended half-life. The Fc region of human IgG1 is generally chosen as the fusion partner for the effector molecule(s) because it extends the fusion protein half-life by recycling via the salvage neonatal FcRn receptor and protects the molecule from lysosomal degradation. Each of the fusion proteins has IgG1 Fc as a fusion partner except denileukin-diftitox, which employs a modified diphtheria toxin effector peptide linked to interleukin-2. For six of the Fc fusion proteins, the effector peptide(s) is linked to the N-terminus of the Fc piece but for the thrombopoietin-mimetic romiplostim, linkage is through the C-terminus. Although some clear type I and IV hypersensitivities are known to be induced by fusion protein therapy, the pathomechanisms underlying many adverse hematologic, respiratory, renal, and cutaneous events have generally not been investigated. Assessment of immunogenicity risk is important because a number of immune-based, or influenced, adverse reactions such as anaphylaxis, cutaneous manifestations, infusion, and injection-site reactions, and cytokine release syndrome can occur. Features of many reactions, some autoimmune in nature, suggest type II, III, or IV hypersensitivities. Clinical findings with the anti-arthritis anti-psoriasis biologic etanercept provide the largest body of current knowledge of fusion protein-induced adverse events. For most fusion proteins, little information is available on appropriate diagnostic and desensitization procedures for hypersensitivity and other adverse responses, although skin test concentrations and some successful desensitization protocols have been published for etanercept.

Fusion protein technologies for biopharmaceuticals: Applications and challenges

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy

Impacts of a Zwitterionic Peptide on Its Fusion Protein.

Chimeric Fusion Proteins Used for Therapy: Indications, Mechanisms, and Safety

Fc‐fusion Proteins: New Developments and Future Perspectives

Engineering a Pharmacologically Superior Form of Granulocyte-Colony-stimulating Factor by Fusion with Gelatin-Like-protein Polymer.

Back to the future: recombinant polyclonal antibody therapeutics

A Brief Reminder of Systems of Production and Chromatography-Based Recovery of Recombinant Protein Biopharmaceuticals

Development of Therapeutic Proteins: Advances and Challenges

Recombinant pharmaceuticals from microbial cells: a 2015 update

New protein engineering approaches to multivalent and bispecific antibody fragments

Application of Fusion Protein Technique in Development of Long-acting Drugs

Progression of the Long-term Mechanism and Pharmacokinetics Analysis Technology of Fusion Protein Drugs

Splicing by Overlap Extension PCR for the Production of Fusion Proteins

Polymeric Human Fc-fusion Proteins with Modified Effector Functions.

Use of Transgenic Animals in Biotechnology: Prospects and Problems

Genetic Functionalization of Protein-Based Biomaterials via Protein Fusions

Second-generation biopharmaceuticals

An open source in silico workflow to assist in the design of fusion proteins

Construction and Application of Fusion Protein of Single Chain Variable Fragment